How should the dosage of canafenib/encofenib be adjusted?

Canafenib/Encorafenib is a targeted therapy drug mainly used to treat melanoma containing BRAF V600 mutations, non-small cell lung cancer and colorectal cancer. As a BRAF inhibitor, it can inhibit the proliferation of cancer cells by blocking the signal transduction triggered by the BRAF mutant gene. Since the dosage of this drug is closely related to the patient's tolerance, concomitant medication and other factors, the dosage needs to be adjusted according to different treatment needs and drug interactions.

In the treatment of melanoma and non-small cell lung cancer, the initial dose of encofenib is usually 300 mg once daily, usually consisting of four 75 mg capsules. For some patients, the initial dose may need to be adjusted based on tolerance. If the patient has poor tolerance to the 300 mg dose, the second dose can be adjusted to 225 mg once daily, which is three 75 mg capsules. If the patient still cannot tolerate the 225 mg dose, encofenib needs to be permanently discontinued.

Encofenib dose adjustments are more stringent in patients with colorectal cancer. The initial dose is usually 225 mg (three 75 mg capsules) once daily, and this dose can be continued if the patient tolerates it well. If the patient does not tolerate the 225 mg dose, the dose can be reduced to 150 mg once daily, which is two 75 mg capsules. Patients who are still intolerant at the 150 mg dose should consider discontinuing the drug.

In addition, the dosage adjustment of encofenib also needs to consider the combined use with other drugs, especially the combined use withCYP3A4 inhibitors. Concomitant use of encofenib and strong or moderate CYP3A4 inhibitors should be avoided. If combination therapy is unavoidable, encofenib should be resumed at the original dose after 3 to 5 half-lives of discontinuation of the CYP3A4 inhibitor. This is because CYP3A4 inhibitors can affect the metabolic process of encofenib, resulting in excessive drug concentration, thereby increasing the risk of side effects.

Reference materials:https://www.braftovi.com/